Rarity PBC

Rarity Bioscience is a Swedish molecular biotechnology company specializing in ultra-sensitive nucleic acid detection. The company's core technology, SuperRCA, is a multiplex assay capable of detecting rare genetic mutations with a sensitivity of 1 in 100,000, significantly outperforming standard liquid biopsy methods. Rarity focuses on providing tools for Minimal Residual Disease (MRD) monitoring and early cancer detection, enabling clinicians to identify relapse earlier and optimize treatment strategies. Their platform is designed to be compatible with existing laboratory infrastructure, such as flow cytometers, making high-sensitivity mutation testing more accessible.